Two Cases of Diabetes Remission Through Temporary Tirzepatide Treatment

In real-world settings, the incidence of diabetes remission remains low. The factors identified as being associated with diabetes remission included a short duration of diabetes, low baseline hemoglobin A1c (HbA1c) levels, absence of ongoing diabetes pharmacotherapy, and post-intervention weight reduction. However, substantial weight reduction is difficult to achieve in routine clinical practice. Tirzepatide is a novel antidiabetic agent that functions as a dual agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Clinical trials have shown that tirzepatide significantly reduces HbA1c levels and induces substantial weight reduction. We herein report two cases of diabetes remission after temporary tirzepatide therapy.